Flex Pharma Inc (FLKS) was Downgraded by Cantor Fitzgerald to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Cantor Fitzgerald advised their investors in a research report released on Oct 14, 2016.
Flex Pharma Inc closed down -0.12 points or -1.02% at $11.61 with 50,371 shares getting traded on Tuesday. Post opening the session at $11.63, the shares hit an intraday low of $11.31 and an intraday high of $11.67 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jul 12, 2016, John Sculley (director) purchased 4,709 shares at $11.60 per share price. According to the SEC, on Jun 24, 2016, Christoph H Westphal (CEO) purchased 2,700 shares at $11.28 per share price. On Mar 16, 2016, Michelle Stacy (director) purchased 2,585 shares at $9.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Flex Pharma Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company’s treatment which forms the basis of both drug product and consumer product development efforts activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company’s pre-clinical drug product candidates are offered for Nocturnal leg cramps and MS spasticity cervical dystonia and/or SCI spasticity. The Company’s consumer brand and products focuses athletes experiencing exercise-associated muscle cramps or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.